Given that developing effective and selective inhibitors of STAT3 remains challenging, very recently, the Wang group developed potent and specific PROTAC degraders targeting STAT3 that showed great in vivo therapeutic potential for AML and anaplastic large-cell lymphoma (ALCL)321 (Fig. 40). The gene discussed is STAT3; the disease is acute myeloid leukemia.